Newsroom
Sorted by: Latest
-
Insight Enterprises, Inc. to Report First Quarter 2026 Financial Results on May 7, 2026
CHANDLER, Ariz.--(BUSINESS WIRE)--Insight Enterprises, Inc. (Nasdaq: NSIT) today announced that it will release financial results for the quarter ended March 31, 2026, prior to market open on May 7, 2026, and will also host a conference call and live webcast at 9:00 a.m. ET to discuss the results of operations. The live webcast and replays of the conference call can be accessed at: http://investor.insight.com/. To access the live conference call, please register in advance using this event link...
-
Arlo Acquires Aloe Care Health, Expanding Arlo SaaS Platform to Support Aging in Place and Wellness Care
SAN JOSE, Calif.--(BUSINESS WIRE)--Arlo Technologies, Inc. (NYSE: ARLO), a leading provider of smart security services, announced today that it has completed the acquisition of Aloe Care Health, a leading AI-powered medical alert and fall prevention platform that delivers improved outcomes for patients and their caregivers. With 87% of adults over 65 looking to stay in their current home and 90% of U.S. homes not “aging ready” according to the U.S. Department of Health and Human Services, the a...
-
Cerus Corporation to Release First Quarter 2026 Financial Results on April 30, 2026
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that its first quarter 2026 financial results will be released on Thursday, April 30, 2026, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the Company’s financial results and provide a general business overview and outlook. To listen to the live webcast and view the presentation slides, please visit the...
-
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that, effective on April 15, 2026, it granted stock options to purchase an aggregate of 129,565 shares of common stock to fourt...
-
Janux Therapeutics Announces First Participant Dosed in Phase 1 Study of JANX014
SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today announced that the first patient has been dosed in a Phase 1 clinical trial of JANX014 in patients with metastatic castration-resistant prostate cancer (mCRPC). JANX014 is a double-masked, prostate-specific membrane antigen (PSMA) directed T cell engager (TCE) designed to leverage Janux’s tumor-activated technology pl...
-
Cohu To Announce First Quarter Financial Results on April 30
SAN DIEGO--(BUSINESS WIRE)--Cohu, Inc. (NASDAQ: COHU), a global supplier of equipment and services optimizing semiconductor manufacturing yield and productivity, will release financial results for first quarter 2026 on Thursday, April 30, 2026, at 1:00 p.m. Pacific Time/4:00 p.m. Eastern Time. The Company will host a live conference call and webcast with presentation materials to discuss the results at 1:30 p.m. Pacific Time/4:30 p.m. Eastern Time. Interested parties may listen live via webcast...
-
FVCBankcorp, Inc. Announces Increase in Quarterly Cash Dividend
FAIRFAX, Va.--(BUSINESS WIRE)--FVCBankcorp, Inc. (NASDAQ: FVCB) (the “Company”) today announced that the Company’s Board of Directors has declared a cash dividend of $0.07 for each share of its common stock outstanding, an increase of $0.01, or 17%, from the previous quarterly cash dividend. The dividend is payable on May 18, 2026 to shareholders of record on April 27, 2026. The declaration and payment of future dividends are subject to the sole discretion of the Board of Directors in addition...
-
CLEARWATER ANALYTICS HOLDINGS, INC. INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Investigates Clearwater Analytics Holdings, Inc.’s Directors for Breach of Fiduciary Duties – CWAN
NEW YORK--(BUSINESS WIRE)--Scott+Scott Attorneys at Law LLP has launched an urgent investigation into whether the directors of Clearwater Analytics Holdings, Inc. (NYSE: CWAN) breached their fiduciary duties to Clearwater’s shareholders in approving a buyout by Warburg Pincus LLC and Permira Advisers LLC. Attorney Joseph A. Pettigrew is heading the investigation—what shareholders need to know:On December 20, 2025, Clearwater announced it had entered into an agreement to be bought out by an inves...
-
OFS Credit Company Declares Monthly Common Stock Cash Distributions
CHICAGO--(BUSINESS WIRE)--OFS Credit Company, Inc. (Nasdaq: OCCI) (“OFS Credit,” the “Company,” “we,” “us” or “our”), an investment company that primarily invests in collateralized loan obligation (“CLO”) equity and debt securities, today announced that its board of directors (the “Board”) declared monthly cash distributions of $0.05 per share of common stock for each of the three months in the quarter ending July 31, 2026. The following schedule applies to the common stock (Nasdaq: OCCI) distr...
-
Riassunto: Perma-Pipe International Holdings, Inc. annuncia risultati da record per il quarto trimestre e l'anno fiscale 2025, con un aumento del 33% delle vendite nette e una crescita dell'89% dell'utile netto
THE WOODLANDS, Texas--(BUSINESS WIRE)--Perma-Pipe International Holdings, Inc. (NASDAQ: PPIH) ha annunciato oggi i risultati finanziari per il quarto trimestre e l'esercizio fiscale 2025 conclusosi il 31 gennaio 2026. Il testo originale del presente annuncio, redatto nella lingua di partenza, è la versione ufficiale che fa fede. Le traduzioni sono offerte unicamente per comodità del lettore e devono rinviare al testo in lingua originale, che è l'unico giuridicamente valido....